- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
Aeterna Zentaris is a biotechnology business based in the US. Aeterna Zentaris shares (AEZS) are listed on the NASDAQ and all prices are listed in US Dollars.
What's in this guide?
Our top picks for where to buy Aeterna Zentaris stock
- Trade $0 commission stocks & ETFs with as little as $1
- Theme and ETF screener
- Discover new opportunities with Opto's AI-driven classification system
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
How to buy Aeterna Zentaris stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – AEZS. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Aeterna Zentaris stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Aeterna Zentaris stock price (NASDAQ: AEZS)
Use our graph to track the performance of AEZS stocks over time.Aeterna Zentaris shares at a glance
52-week range | $3.96 - $11.10 |
---|---|
50-day moving average | $5.61 |
200-day moving average | $5.42 |
Wall St. target price | $15.00 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | $-2.31 |
Is it a good time to buy Aeterna Zentaris stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Aeterna Zentaris financials
Revenue TTM | $2.4 million |
---|---|
Gross profit TTM | $5.2 million |
Return on assets TTM | -29.96% |
Return on equity TTM | -81.71% |
Profit margin | 0% |
Book value | $10.68 |
Market Capitalization | $17.5 million |
TTM: trailing 12 months
Aeterna Zentaris share dividends
We're not expecting Aeterna Zentaris to pay a dividend over the next 12 months.
Have Aeterna Zentaris's shares ever split?
Aeterna Zentaris's shares were split on a 0.0236:1 basis on 6 June 2024 . So if you had owned 1 share the day before before the split, the next day you'd have owned 0.0236 shares. This wouldn't directly have changed the overall worth of your Aeterna Zentaris shares – just the quantity. However, indirectly, the new 4137.3% higher share price could have impacted the market appetite for Aeterna Zentaris shares which in turn could have impacted Aeterna Zentaris's share price.
Aeterna Zentaris share price volatility
Over the last 12 months, Aeterna Zentaris's shares have ranged in value from as little as $3.96 up to $11.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aeterna Zentaris's is 2.257. This would suggest that Aeterna Zentaris's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Aeterna Zentaris overview
Aeterna Zentaris Inc. , a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism.
Frequently asked questions
nullWhat percentage of Aeterna Zentaris is owned by insiders or institutions?
Currently 1.321% of Aeterna Zentaris shares are held by insiders and 5.213% by institutions. When does the fiscal year end for Aeterna Zentaris?
Aeterna Zentaris's fiscal year ends in December. Where is Aeterna Zentaris based?
Aeterna Zentaris's address is: 222 Bay Street, Toronto, Canada, M5K 1E7 What is Aeterna Zentaris's ISIN number?
Aeterna Zentaris's international securities identification number is: CA0079754028 What is Aeterna Zentaris's CUSIP number?
Aeterna Zentaris's Committee on Uniform Securities Identification Procedures number is: 007975105
More guides on Finder
-
Robinhood Now Let’s You Trade on the Outcome of the Presidential Election; Joining Kalshi and others.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
Trading for Beginners: 9 Best Trading Platforms to Get Started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
SoFi Invest vs. Robinhood
Compare pros, cons, research tools and reviews for these two trading platforms.
-
10 Best Stock Apps of 2024 to Elevate Your Mobile Trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
10 Best Brokerage Accounts for Trading and Investing in 2024
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
-
How to Invest $20K: 8 Ways to Maximize Earnings
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
-
Robinhood Review 2024: IRA Match and No Commissions
A deep dive into the highlights and limitations of Robinhood.
Ask a question